EBITDA: Income before interest, taxes, depreciation and amortization.
Aptose Biosciences, Inc. (APTOF) had EBITDA of $-25.85M for the most recently reported fiscal year, ending 2024-12-31.
| Income Statement Financials | |
-- |
|
$-25.43M |
|
-- |
|
-- |
|
$26.26M |
|
$-26.26M |
|
$0.83M |
|
$-25.43M |
|
$-25.43M |
|
$-25.43M |
|
$-25.43M |
|
$-25.43M |
|
$-25.43M |
|
$-26.26M |
|
|
EBITDA |
$-25.85M |
0.70M |
|
0.70M |
|
$-36.38 |
|
$-36.38 |
|
| Balance Sheet Financials | |
$9.53M |
|
$0.03M |
|
$0.60M |
|
$10.13M |
|
$4.46M |
|
$10.02M |
|
$10.21M |
|
$14.67M |
|
$-4.54M |
|
$-4.54M |
|
$-4.54M |
|
2.01M |
|
| Cash Flow Statement Financials | |
$-35.98M |
|
$0.02M |
|
$33.41M |
|
$9.25M |
|
$6.71M |
|
$-2.54M |
|
$1.06M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
2.14 |
|
-- |
|
-- |
|
1.83 |
|
-2.21 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-35.96M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
559.76% |
|
559.76% |
|
-251.11% |
|
-464.47% |
|
$-2.26 |
|
$-51.45 |
|
$-51.47 |
|